NYSEAMERICAN:IGC IGC Pharma (IGC) Stock Forecast, Price & News $0.30 -0.01 (-3.22%) (As of 06/9/2023 ET) Add Compare Share Share Today's Range$0.30▼$0.3250-Day Range N/A52-Week Range$0.28▼$0.74Volume124,205 shsAverage Volume136,655 shsMarket Capitalization$15.98 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media About IGC Pharma (NYSEAMERICAN:IGC) StockIGC Pharma, Inc. engages in the development and commercialization of cannabinoid based alternative therapies for indications, such as Alzheimer's disease, Parkinson's disease, and pain. The firm is involved in researching the application of cannabinoids, such as Tetrahydrocannabinol and Cannabidiol in combination with other compounds to address various ailments, including Alzheimer's disease. It operates through the Infrastructure Business and Life Sciences segments. The Infrastructure Business segment is involved in the rental of heavy construction equipment, execution of construction contracts, and purchase and resale of physical commodities used in infrastructure. The Life Sciences segment includes a biotech component, and a vertically integrated hemp-cannabinoid based healthcare and wellness business, which involves the production of plant and cannabinoid-based products, and therapies. The company was founded by Ram Mukunda on April 29, 2005 and is headquartered in Potomac, MD.Read More Receive IGC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IGC Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address IGC Stock News HeadlinesJune 6, 2023 | finance.yahoo.comIGC Pharma Receives Notice of Allowance for Patent on SeizuresJune 5, 2023 | finance.yahoo.comIGC Pharma’s Advisor and Inventor of Drug Candidate TGR-63 Receives AwardJune 10, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.May 18, 2023 | finance.yahoo.comIGC Pharma to Present at LD Micro Invitational XIIIMay 8, 2023 | marketwatch.com8-K: IGC Pharma, Inc.April 30, 2023 | americanbankingnews.comIGC Pharma (NYSEAMERICAN:IGC) Stock Passes Above Two Hundred Day Moving Average of $0.00April 19, 2023 | marketwatch.comBioMedNewsBreaks - IGC Pharma Inc. (NYSE American: IGC) Announces Participation in Upcoming Planet MicroCap ShowcaseApril 18, 2023 | finance.yahoo.comIGC Pharma, Inc. to Present at the Planet MicroCap Showcase: VEGAS 2023 on Wednesday, April 26, 2023 & Hold 1x1 Meetings on Thursday, April 27, 2023June 10, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.March 22, 2023 | marketwatch.comBioMedNewsBreaks - IGC Pharma Inc. (NYSE American: IGC) to Attend Investor SummitMarch 22, 2023 | finance.yahoo.comIGC Pharma to Attend Investor SummitMarch 20, 2023 | finance.yahoo.comIGC Announces Rebranding, Changes Name to IGC Pharma, Inc.March 5, 2023 | benzinga.comIndia Globalization Capital Inc. (NYSE American: IGC) Leads the Way Forward with Revolutionary Cannabis-Based Treatment for Alzheimer's SymptomsFebruary 15, 2023 | msn.comIndia Globalization Capital GAAP EPS of -$0.04, revenue of $0.33MFebruary 15, 2023 | benzinga.comIGC Q3 2023 Revenue Grows 133% YoY, What About Net Loss?February 14, 2023 | finance.yahoo.comIGC Reports Financial Results for Third Fiscal Quarter Ended Dec. 31, 2022February 8, 2023 | finance.yahoo.comIGC to be Featured in Feb. 10 Radius Research Investor WebinarJanuary 27, 2023 | reuters.comIGC.P - | Stock Price & Latest News | ReutersJanuary 5, 2023 | benzinga.comIndia Globalization Cap Stock (AMEX:IGC), Quotes and News SummaryJanuary 4, 2023 | finance.yahoo.comIGC Receives No Objection Letter from Health CanadaDecember 20, 2022 | finance.yahoo.comIGC Announces Updated Life Sciences PresentationDecember 7, 2022 | finance.yahoo.comIGC Applauds Signing of Bipartisan Medical Marijuana and Cannabidiol Research Expansion ActDecember 1, 2022 | finance.yahoo.comIGC Commences Phase 2 Clinical Trials Evaluating Drug Candidate IGC-AD1 for the Treatment of Agitation in Dementia From Alzheimer’s DiseaseNovember 30, 2022 | finance.yahoo.comIGC to Present at the RHK 2022 Disruptive Growth ConferenceNovember 1, 2022 | finance.yahoo.comIGC Reports Financial Results for Second Fiscal Quarter Ended Sept. 30, 2022September 21, 2022 | seekingalpha.comIndia Globalization stock rises on US patent linked to treating Alzheimer's using THCSeptember 21, 2022 | finance.yahoo.comIGC Announces Issuance of Second Patent for the Treatment of Alzheimer’s Using THCSee More Headlines IGC Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IGC Company Calendar Last Earnings2/10/2020Today6/10/2023Next Earnings (Estimated)6/21/2023Fiscal Year End3/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN Industry Electronic parts & equipment, not elsewhere classified Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:IGC CUSIPN/A CIK1326205 Webwww.igcinc.us Phone(301) 983-0998Fax240-465-0273Employees50Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-15,020,000.00 Net Margins-1,610.48% Pretax Margin-1,610.48% Return on Equity-66.26% Return on Assets-60.11% Debt Debt-to-Equity Ratio0.01 Current Ratio6.90 Quick Ratio4.13 Sales & Book Value Annual Sales$400,000.00 Price / Sales39.94 Cash FlowN/A Price / Cash FlowN/A Book Value$0.47 per share Price / Book0.64Miscellaneous Outstanding Shares53,080,000Free Float44,850,000Market Cap$15.98 million OptionableOptionable Beta2.32 Key ExecutivesRam MukundaPresident, Chief Executive Officer & DirectorClaudia GrimaldiCFO, Director, Chief Compliance Officer & VPJagadeesh RaoChief Scientific OfficerRohit GoelChief Accounting OfficerKey CompetitorsBabylonNYSE:BBLNMicrobot MedicalNASDAQ:MBOTAmerican Shared Hospital ServicesNYSEAMERICAN:AMSLotus PharmaceuticalsOTCMKTS:LTUSSynthetic BiologicsNYSEAMERICAN:SYNView All CompetitorsInstitutional OwnershipSusquehanna International Group LLPSold 1,200 shares on 5/16/2023Ownership: 0.000%Renaissance Technologies LLCSold 111,711 shares on 5/12/2023Ownership: 0.208%Group One Trading L.P.Bought 6,000 shares on 5/12/2023Ownership: 0.000%Simplex Trading LLCSold 10,700 shares on 4/27/2023Ownership: 0.000%View All Institutional Transactions IGC Stock - Frequently Asked Questions How have IGC shares performed in 2023? IGC Pharma's stock was trading at $0.40 at the beginning of the year. Since then, IGC shares have decreased by 24.8% and is now trading at $0.3010. View the best growth stocks for 2023 here. Are investors shorting IGC Pharma? IGC Pharma saw a decrease in short interest in May. As of May 15th, there was short interest totaling 896,700 shares, a decrease of 14.6% from the April 30th total of 1,050,000 shares. Based on an average daily volume of 102,400 shares, the days-to-cover ratio is currently 8.8 days. View IGC Pharma's Short Interest. When is IGC Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 21st 2023. View our IGC earnings forecast. How were IGC Pharma's earnings last quarter? IGC Pharma, Inc. (NYSEAMERICAN:IGC) announced its quarterly earnings data on Monday, February, 10th. The construction company reported ($0.04) earnings per share (EPS) for the quarter. The construction company earned $0.57 million during the quarter. IGC Pharma had a negative trailing twelve-month return on equity of 66.26% and a negative net margin of 1,610.48%. What other stocks do shareholders of IGC Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other IGC Pharma investors own include GW Pharmaceuticals (GWPH), Alibaba Group (BABA), Tilray (TLRY), Cronos Group (CRON), Micron Technology (MU), NewAge (NBEV), Advanced Micro Devices (AMD), Ford Motor (F) and NIO (NIO). What is IGC Pharma's stock symbol? IGC Pharma trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "IGC." Who are IGC Pharma's major shareholders? IGC Pharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (0.21%), Susquehanna International Group LLP (0.00%), Group One Trading L.P. (0.00%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Ram Mukunda and Richard K Prins. View institutional ownership trends. How do I buy shares of IGC Pharma? Shares of IGC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is IGC Pharma's stock price today? One share of IGC stock can currently be purchased for approximately $0.30. How much money does IGC Pharma make? IGC Pharma (NYSEAMERICAN:IGC) has a market capitalization of $15.98 million and generates $400,000.00 in revenue each year. The construction company earns $-15,020,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis. How can I contact IGC Pharma? IGC Pharma's mailing address is 4336 Montgomery Ave, BETHESDA, MD 20814-4443, United States. The official website for the company is www.igcinc.us. The construction company can be reached via phone at (301) 983-0998, via email at info@igcinc.us, or via fax at 240-465-0273. This page (NYSEAMERICAN:IGC) was last updated on 6/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IGC Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.